BIIBBiogen Inc
$209.03
$9.88
(4.96%)
Closed $209.03
$0.03
(0.01%)
After Hours
/filters:format(webp)https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/large_biogen_fda_resized_3ea96b95df.jpg)
EarningsJul 29
Mkt Cap$29.4B
Vol2.26M
FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease PR Newswire TOKYO and CAMBRIDGE, Mass., July 13, 2026 LEQEMBI...
PR Newswire
New drug data could lift shares of this biotechnology stock, Truist says
Biogen could see more upside if it publishes positive results from recent trials linked to kidney and Alzheimer's treatments, Truist Securities says...
CNBC: Top News
Here are Monday's biggest analyst calls: Nvidia, SpaceX, Tesla, Apple, Netflix, Deckers, Biogen, Nio & more
Here are Monday's biggest calls on Wall Street...
CNBC: Top News
Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet...
Business Wire
This Biogen Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Top Wall Street analysts changed their outlook on top names. Upgrade on NIO, COF, KEYS, BIIB, and AXP, see other ratings and consider buying BIIB.read more...
Benzinga
LEQEMBI Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference (AAIC) 2026
LEQEMBI Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference (AAIC) 2026 LEQEMBI Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to...
PR Newswire
DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?
Denali Therapeutics surges on Avlayah???s FDA approval, PRV sale and pipeline progress, but partnership changes and trial setbacks remain in focus.
Zacks
IONS Completes Enrollment in Pivotal Cohort of Angelman Syndrome Study
Ionis completes enrollment in the pivotal pediatric cohort of its phase III REVEAL study, advancing obudanersen toward potential regulatory submissions.
Zacks
Why Biogen (BIIB) is Poised to Beat Earnings Estimates Again
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks
<
1
2
...
>
Advertisement|Remove ads.
Latest BIIB News
ViewFDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
PR Newswire
BIIB Stock Jumps 5% — Analysts Raise Price Targets After FDA Clears Alzheimer’s Treatment For At-Home Use
Stocktwits
New drug data could lift shares of this biotechnology stock, Truist says
CNBC: Top News
Advertisement|Remove ads.